Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 169

1.

Assessing the lymphoid tissue bioavailability of antiretrovirals in human primary lymphoid endothelial cells and in mice.

Dyavar SR, Gautam N, Podany AT, Winchester LC, Weinhold JA, Mykris TM, Campbell KM, Alnouti Y, Fletcher CV.

J Antimicrob Chemother. 2019 Jul 23. pii: dkz273. doi: 10.1093/jac/dkz273. [Epub ahead of print]

PMID:
31335938
2.

Impact of Integrase Inhibition Compared With Nonnucleoside Inhibition on HIV Reservoirs in Lymphoid Tissues.

Rothenberger M, Nganou-Makamdop K, Kityo C, Ssali F, Chipman JG, Beilman GJ, Hoskuldsson T, Anderson J, Jasurda J, Schmidt TE, Calisto SP, Pearson H, Reimann T, David C, Perkey K, Southern P, Wietgrefe S, Helgeson E, Reilly C, Haase AT, Douek DC, Fletcher CV, Schacker TW.

J Acquir Immune Defic Syndr. 2019 Jul 1;81(3):355-360. doi: 10.1097/QAI.0000000000002026.

3.

One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.

Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, Jean Juste MA, Lama JR, Valencia J, Omoz-Oarhe A, Supparatpinyo K, Masheto G, Mohapi L, da Silva Escada RO, Mawlana S, Banda P, Severe P, Hakim J, Kanyama C, Langat D, Moran L, Andersen J, Fletcher CV, Nuermberger E, Chaisson RE; BRIEF TB/A5279 Study Team.

N Engl J Med. 2019 Mar 14;380(11):1001-1011. doi: 10.1056/NEJMoa1806808.

4.

Transplantation of CCR5∆32 Homozygous Umbilical Cord Blood in a Child With Acute Lymphoblastic Leukemia and Perinatally Acquired HIV Infection.

Rothenberger M, Wagner JE, Haase A, Richman D, Grzywacz B, Strain M, Lada S, Estes J, Fletcher CV, Podany AT, Anderson J, Schmidt T, Wietgrefe S, Schacker T, Verneris MR.

Open Forum Infect Dis. 2018 May 22;5(5):ofy090. doi: 10.1093/ofid/ofy090. eCollection 2018 May.

5.

Adipocytes impair efficacy of antiretroviral therapy.

Couturier J, Winchester LC, Suliburk JW, Wilkerson GK, Podany AT, Agarwal N, Xuan Chua CY, Nehete PN, Nehete BP, Grattoni A, Sastry KJ, Fletcher CV, Lake JE, Balasubramanyam A, Lewis DE.

Antiviral Res. 2018 Jun;154:140-148. doi: 10.1016/j.antiviral.2018.04.002. Epub 2018 Apr 6.

6.

Development, validation and utilization of a highly sensitive LC-MS/MS method for quantification of levonorgestrel released from a subdermal implant in human plasma.

Cirrincione LR, Penchala SD, Scarsi KK, Podany AT, Winchester LC, Back DJ, Khoo SH, Fletcher CV, Siccardi M, Else LJ.

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 May 1;1084:106-112. doi: 10.1016/j.jchromb.2018.03.023. Epub 2018 Mar 12.

7.

Cumulative Antiretroviral Exposure Measured in Hair Is Not Associated With Measures of HIV Persistence or Inflammation Among Individuals on Suppressive ART.

Gandhi M, Gandhi RT, Stefanescu A, Bosch RJ, Cyktor JC, Horng H, Louie A, Phung N, Eron JJ, Hogg E, Macatangay BJC, Hensel C, Fletcher CV, Mellors JW, McMahon DK; A5321 Team.

J Infect Dis. 2018 Jun 20;218(2):234-238. doi: 10.1093/infdis/jiy011.

8.

Normalization of cell associated antiretroviral drug concentrations with a novel RPP30 droplet digital PCR assay.

Dyavar SR, Ye Z, Byrareddy SN, Scarsi KK, Winchester LC, Weinhold JA, Fletcher CV, Podany AT.

Sci Rep. 2018 Feb 26;8(1):3626. doi: 10.1038/s41598-018-21882-0.

9.

Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug-drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART.

Roberts O, Rajoli RKR, Back DJ, Owen A, Darin KM, Fletcher CV, Lamorde M, Scarsi KK, Siccardi M.

J Antimicrob Chemother. 2018 Apr 1;73(4):1004-1012. doi: 10.1093/jac/dkx515.

10.

Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.

Podany AT, Bares SH, Havens J, Dyavar SR, O'Neill J, Lee S, Fletcher CV, Swindells S, Scarsi KK.

AIDS. 2018 Mar 27;32(6):761-765. doi: 10.1097/QAD.0000000000001744.

11.

Lorenzo-Redondo et al. reply.

Lorenzo-Redondo R, Fryer HR, Bedford T, Kim EY, Archer J, Pond SLK, Chung YS, Penugonda S, Chipman JG, Fletcher CV, Schacker TW, Malim MH, Rambaut A, Haase AT, McLean AR, Wolinsky SM.

Nature. 2017 Nov 22;551(7681):E10. doi: 10.1038/nature24635. No abstract available.

PMID:
29168807
12.

Defining total-body AIDS-virus burden with implications for curative strategies.

Estes JD, Kityo C, Ssali F, Swainson L, Makamdop KN, Del Prete GQ, Deeks SG, Luciw PA, Chipman JG, Beilman GJ, Hoskuldsson T, Khoruts A, Anderson J, Deleage C, Jasurda J, Schmidt TE, Hafertepe M, Callisto SP, Pearson H, Reimann T, Schuster J, Schoephoerster J, Southern P, Perkey K, Shang L, Wietgrefe SW, Fletcher CV, Lifson JD, Douek DC, McCune JM, Haase AT, Schacker TW.

Nat Med. 2017 Nov;23(11):1271-1276. doi: 10.1038/nm.4411. Epub 2017 Oct 2.

13.

Impact of efavirenz pharmacokinetics and pharmacogenomics on neuropsychological performance in older HIV-infected patients.

Sandkovsky U, Podany AT, Fletcher CV, Owen A, Felton-Coleman A, Winchester LC, Robertson K, Swindells S.

J Antimicrob Chemother. 2017 Jan;72(1):200-204. Epub 2016 Sep 21.

14.

Etravirine Pharmacokinetics in HIV-Infected Pregnant Women.

Mulligan N, Schalkwijk S, Best BM, Colbers A, Wang J, Capparelli EV, Moltó J, Stek AM, Taylor G, Smith E, Hidalgo Tenorio C, Chakhtoura N, van Kasteren M, Fletcher CV, Mirochnick M, Burger D.

Front Pharmacol. 2016 Aug 4;7:239. doi: 10.3389/fphar.2016.00239. eCollection 2016.

15.

Alterations in P-Glycoprotein Expression and Function Between Macrophage Subsets.

Cory TJ, He H, Winchester LC, Kumar S, Fletcher CV.

Pharm Res. 2016 Nov;33(11):2713-21. doi: 10.1007/s11095-016-1998-x. Epub 2016 Jul 18.

16.

Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors.

Podany AT, Scarsi KK, Fletcher CV.

Clin Pharmacokinet. 2017 Jan;56(1):25-40. doi: 10.1007/s40262-016-0424-1. Review.

17.

Pharmacokinetics of Darunavir/Ritonavir With Etravirine Both Twice Daily in Human Immunodeficiency Virus-Infected Adolescents and Young Adults.

Cressey TR, Yogev R, Wiznia A, Hazra R, Jean-Philippe P, Graham B, Gonzalez A, Britto P, Carey VJ, Fletcher CV, Acosta EP; IMPAACT P1058A Team.

J Pediatric Infect Dis Soc. 2017 Sep 1;6(3):294-296. doi: 10.1093/jpids/piw017.

18.

Antiretroviral drug transporters and metabolic enzymes in human testicular tissue: potential contribution to HIV-1 sanctuary site.

Huang Y, Hoque MT, Jenabian MA, Vyboh K, Whyte SK, Sheehan NL, Brassard P, Bélanger M, Chomont N, Fletcher CV, Routy JP, Bendayan R.

J Antimicrob Chemother. 2016 Jul;71(7):1954-65. doi: 10.1093/jac/dkw046. Epub 2016 Apr 13.

19.

Topical Tenofovir Disoproxil Fumarate Nanoparticles Prevent HIV-1 Vaginal Transmission in a Humanized Mouse Model.

Destache CJ, Mandal S, Yuan Z, Kang G, Date AA, Lu W, Shibata A, Pham R, Bruck P, Rezich M, Zhou Y, Vivekanandan R, Fletcher CV, Li Q.

Antimicrob Agents Chemother. 2016 May 23;60(6):3633-9. doi: 10.1128/AAC.00450-16. Print 2016 Jun.

20.

Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342).

Castillo-Mancilla JR, Aquilante CL, Wempe MF, Smeaton LM, Firnhaber C, LaRosa AM, Kumarasamy N, Andrade A, Baheti G, Fletcher CV, Campbell TB, Haas DW, MaWhinney S, Anderson PL.

J Antimicrob Chemother. 2016 Jun;71(6):1609-18. doi: 10.1093/jac/dkw005. Epub 2016 Feb 17.

21.

Persistent HIV-1 replication maintains the tissue reservoir during therapy.

Lorenzo-Redondo R, Fryer HR, Bedford T, Kim EY, Archer J, Pond SLK, Chung YS, Penugonda S, Chipman J, Fletcher CV, Schacker TW, Malim MH, Rambaut A, Haase AT, McLean AR, Wolinsky SM.

Nature. 2016 Feb 4;530(7588):51-56. doi: 10.1038/nature16933. Epub 2016 Jan 27.

22.

Nevirapine Plasma Concentrations in Human Immunodeficiency Virus-Exposed Neonates Receiving High-Dose Nevirapine Prophylaxis as Part of 3-Drug Regimen.

Bolaris MA, Keller MA, Robbins BL, Podany AT, Fletcher CV.

J Pediatric Infect Dis Soc. 2017 Mar 1;6(1):102-104. doi: 10.1093/jpids/piv084. No abstract available.

PMID:
26803329
23.

A rapid spin through oil results in higher cell-associated concentrations of antiretrovirals compared with conventional cell washing.

Cory TJ, Winchester LC, Robbins BL, Fletcher CV.

Bioanalysis. 2015;7(12):1447-55. doi: 10.4155/bio.15.70.

24.

Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention.

Podany AT, Bao Y, Swindells S, Chaisson RE, Andersen JW, Mwelase T, Supparatpinyo K, Mohapi L, Gupta A, Benson CA, Kim P, Fletcher CV; AIDS Clinical Trials Group A5279 Study Team.

Clin Infect Dis. 2015 Oct 15;61(8):1322-7. doi: 10.1093/cid/civ464. Epub 2015 Jun 16.

25.

Pharmacokinetics of tenofovir during pregnancy and postpartum.

Best BM, Burchett S, Li H, Stek A, Hu C, Wang J, Hawkins E, Byroads M, Watts DH, Smith E, Fletcher CV, Capparelli EV, Mirochnick M; International Maternal Pediatric and Adolescent AIDS Clinical Trials (IMPAACT) P1026s Team.

HIV Med. 2015 Sep;16(8):502-11. doi: 10.1111/hiv.12252. Epub 2015 May 11.

26.

Plasma and Intracellular Pharmacokinetics of Tenofovir Disoproxil Fumarate 300 mg Every 48 Hours vs 150 mg Once Daily in HIV-Infected Adults With Moderate Renal Function Impairment.

Cressey TR, Avihingsanon A, Halue G, Leenasirimakul P, Sukrakanchana PO, Tawon Y, Jaisieng N, Jourdain G, Podany AT, Fletcher CV, Klinbuayaem V, Bowonwatanuwong C.

Clin Infect Dis. 2015 Aug 15;61(4):633-9. doi: 10.1093/cid/civ346. Epub 2015 Apr 28.

27.

Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption.

Rothenberger MK, Keele BF, Wietgrefe SW, Fletcher CV, Beilman GJ, Chipman JG, Khoruts A, Estes JD, Anderson J, Callisto SP, Schmidt TE, Thorkelson A, Reilly C, Perkey K, Reimann TG, Utay NS, Nganou Makamdop K, Stevenson M, Douek DC, Haase AT, Schacker TW.

Proc Natl Acad Sci U S A. 2015 Mar 10;112(10):E1126-34. doi: 10.1073/pnas.1414926112. Epub 2015 Feb 23.

28.

Determination of the rifamycin antibiotics rifabutin, rifampin, rifapentine and their major metabolites in human plasma via simultaneous extraction coupled with LC/MS/MS.

Winchester LC, Podany AT, Baldwin JS, Robbins BL, Fletcher CV.

J Pharm Biomed Anal. 2015 Feb;104:55-61. doi: 10.1016/j.jpba.2014.11.011. Epub 2014 Nov 18.

29.

Editorial commentary: cerebrospinal fluid inhibitory quotients of antiretroviral drugs.

Fletcher CV.

Clin Infect Dis. 2015 Jan 15;60(2):318-20. doi: 10.1093/cid/ciu775. Epub 2014 Oct 3. No abstract available.

PMID:
25281611
30.

Antifibrotic therapy in simian immunodeficiency virus infection preserves CD4+ T-cell populations and improves immune reconstitution with antiretroviral therapy.

Estes JD, Reilly C, Trubey CM, Fletcher CV, Cory TJ, Piatak M Jr, Russ S, Anderson J, Reimann TG, Star R, Smith A, Tracy RP, Berglund A, Schmidt T, Coalter V, Chertova E, Smedley J, Haase AT, Lifson JD, Schacker TW.

J Infect Dis. 2015 Mar 1;211(5):744-54. doi: 10.1093/infdis/jiu519. Epub 2014 Sep 22.

31.

Long-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: the Pediatric AIDS Clinical Trials Group Protocol 1020A.

Rutstein RM, Samson P, Fenton T, Fletcher CV, Kiser JJ, Mofenson LM, Smith E, Graham B, Mathew M, Aldrovani G; PACTG 1020A Study Team.

Pediatr Infect Dis J. 2015 Feb;34(2):162-7. doi: 10.1097/INF.0000000000000538.

32.

Correlation between plasma, intracellular, and cervical tissue levels of raltegravir at steady-state dosing in healthy women.

Mitchell C, Roemer E, Nkwopara E, Robbins B, Cory T, Rue T, Fletcher CV, Frenkel L.

Antimicrob Agents Chemother. 2014 Jun;58(6):3360-5. doi: 10.1128/AAC.02757-13. Epub 2014 Mar 31.

33.

Quantification of cell-associated atazanavir, darunavir, lopinavir, ritonavir, and efavirenz concentrations in human mononuclear cell extracts.

Podany AT, Winchester LC, Robbins BL, Fletcher CV.

Antimicrob Agents Chemother. 2014 May;58(5):2866-70. doi: 10.1128/AAC.02551-13. Epub 2014 Mar 10.

34.

Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues.

Fletcher CV, Staskus K, Wietgrefe SW, Rothenberger M, Reilly C, Chipman JG, Beilman GJ, Khoruts A, Thorkelson A, Schmidt TE, Anderson J, Perkey K, Stevenson M, Perelson AS, Douek DC, Haase AT, Schacker TW.

Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):2307-12. doi: 10.1073/pnas.1318249111. Epub 2014 Jan 27.

35.

Pharmacometric characterization of efavirenz developmental pharmacokinetics and pharmacogenetics in HIV-infected children.

Salem AH, Fletcher CV, Brundage RC.

Antimicrob Agents Chemother. 2014;58(1):136-43. doi: 10.1128/AAC.01738-13. Epub 2013 Oct 21.

36.

Overcoming pharmacologic sanctuaries.

Cory TJ, Schacker TW, Stevenson M, Fletcher CV.

Curr Opin HIV AIDS. 2013 May;8(3):190-5. doi: 10.1097/COH.0b013e32835fc68a. Review.

37.

Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults.

Baheti G, King JR, Acosta EP, Fletcher CV.

AIDS. 2013 Jan 14;27(2):221-5. doi: 10.1097/QAD.0b013e32835a9a2d.

38.

Measurement of plasma and intracellular concentrations of raltegravir in patients with HIV infection.

Sandkovsky U, Swindells S, Robbins BL, Nelson SR, Acosta EP, Fletcher CV.

AIDS. 2012 Nov 13;26(17):2257-9. doi: 10.1097/QAD.0b013e328359a978.

PMID:
22948265
39.

A novel ultrasensitive LC-MS/MS assay for quantification of intracellular raltegravir in human cell extracts.

Robbins BL, Nelson SR, Fletcher CV.

J Pharm Biomed Anal. 2012 Nov;70:378-87. doi: 10.1016/j.jpba.2012.05.035. Epub 2012 Jun 2.

40.

Isoniazid pharmacokinetics, pharmacodynamics, and dosing in South African infants.

Kiser JJ, Zhu R, DʼArgenio DZ, Cotton MF, Bobat R, McSherry GD, Madhi SA, Carey VJ, Seifart HI, Werely CJ, Fletcher CV.

Ther Drug Monit. 2012 Aug;34(4):446-51. doi: 10.1097/FTD.0b013e31825c4bc3.

41.
42.

Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients.

Baheti G, Kiser JJ, Havens PL, Fletcher CV.

Antimicrob Agents Chemother. 2011 Nov;55(11):5294-9. doi: 10.1128/AAC.05317-11. Epub 2011 Sep 6.

43.

The critical need for alternative antiretroviral formulations, and obstacles to their development.

Swindells S, Flexner C, Fletcher CV, Jacobson JM.

J Infect Dis. 2011 Sep 1;204(5):669-74. doi: 10.1093/infdis/jir370. Epub 2011 Jul 25. No abstract available.

44.

Atazanavir and atazanavir/ritonavir pharmacokinetics in HIV-infected infants, children, and adolescents.

Kiser JJ, Rutstein RM, Samson P, Graham B, Aldrovandi G, Mofenson LM, Smith E, Schnittman S, Fenton T, Brundage RC, Fletcher CV.

AIDS. 2011 Jul 31;25(12):1489-96. doi: 10.1097/QAD.0b013e328348fc41.

45.

The pharmacogenetics of NAT2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid.

Zhu R, Kiser JJ, Seifart HI, Werely CJ, Mitchell CD, D'Argenio DZ, Fletcher CV.

J Clin Pharmacol. 2012 Apr;52(4):511-9. doi: 10.1177/0091270011402826. Epub 2011 May 10.

46.

Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men.

Umeh OC, Currier JS, Park JG, Cramer Y, Hermes AE, Fletcher CV.

J Clin Pharmacol. 2011 Dec;51(12):1665-73. doi: 10.1177/0091270010388650. Epub 2011 Jan 13.

47.

Accelerator mass spectrometry measurement of intracellular concentrations of active drug metabolites in human target cells in vivo.

Chen J, Garner RC, Lee LS, Seymour M, Fuchs EJ, Hubbard WC, Parsons TL, Pakes GE, Fletcher CV, Flexner C.

Clin Pharmacol Ther. 2010 Dec;88(6):796-800. doi: 10.1038/clpt.2010.188. Epub 2010 Oct 27.

PMID:
20981003
48.

Implications of HIV PrEP trials results.

Veronese F, Anton P, Fletcher CV, DeGruttola V, McGowan I, Becker S, Zwerski S, Burns D; Workshop Organizing Committee.

AIDS Res Hum Retroviruses. 2011 Jan;27(1):81-90. doi: 10.1089/AID.2010.0226. Epub 2010 Dec 12.

49.

Drug interactions should be evaluated in patients.

Fletcher CV.

Clin Pharmacol Ther. 2010 Nov;88(5):585-7. doi: 10.1038/clpt.2010.213.

PMID:
20959842
50.

Clinical evaluation of a dried blood spot assay for atazanavir.

Van Schooneveld T, Swindells S, Nelson SR, Robbins BL, Moore R, Fletcher CV.

Antimicrob Agents Chemother. 2010 Oct;54(10):4124-8. doi: 10.1128/AAC.00297-10. Epub 2010 Jul 26.

Supplemental Content

Loading ...
Support Center